Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0540 • ACR Convergence 2022
Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE
Sandra Jägerback¹, Alvaro Gomez¹ and Ioannis Parodis², ¹Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In patients with systemic lupus erythematosus (SLE), renal involvement is associated with high morbidity, and renal flare is a major contributing factor to poor…
Abstract Number: 0642 • ACR Convergence 2022
SLAMF6-SAP Signaling Unit Is Increased in SLE T Follicular Helper Cells
Yevgeniya Gartshteyn¹, Leila Khalili², Adam Mor³ and Anca Askanase², ¹Columbia University Medical Center, Glen Rock, NJ, ²Columbia University Medical Center, New York, NY, ³Columbia University, New York, NY
Background/Purpose: SLE is a multiorgan disease in which immune cells lack self-tolerance resulting in autoimmunity. SLE T cells infiltrate organs, provide help to autoreactive B…
Abstract Number: 0663 • ACR Convergence 2022
Anti-Erythrocyte Antibodies in Childhood Onset Systemic Lupus Erythematosus
Lauren Robinson¹, Zurong Wan², Preetha Balasubramanian³, Juan Rodriguez Alcazar³, Lynnette Walters⁴, Jeanine Baisch², karen onel⁵, Tracey Wright⁶, Virginia Pascual³ and Simone Caielli³, ¹Hospital for Special Surgery/New York Presbyterian-Weill Cornell, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴Scottish Rite Hospital for Children, Allen, TX, ⁵Hospital for Special Surgery, New York, NY, ⁶UT Southwestern, Plano, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type 1 interferon signature. It…
Abstract Number: 0827 • ACR Convergence 2022
Unpublished Clinical Trials of Major Rheumatic Diseases
Connor Pedersen¹, Mike Putman², Erin Valley¹, Kathryn Henry³, Ali Duarte-Garcia⁴, Shikha Singla⁵ and Shannon Tai¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²The Medical College of Wisconsin, Milwaukee, WI, ³Medical College of Wisconsin, Manitowoc, WI, ⁴Mayo Clinic, Rochester, MN, ⁵MCW, Fox Point, WI
Background/Purpose: Randomized controlled trials (RCTs) provide high-quality evidence for treatment efficacy, but many RCTs remain unpublished. The objective of this study was to describe the…
Abstract Number: 0966 • ACR Convergence 2022
Assessment and Application of Royal College of Obstetricians and Gynaecologists (RCOG) Risk Scores in the Prevention of Venous Thromboembolism Peri- and Postpartum in Systemic Lupus Erythematosus
Alexis Engel¹, Myah Griffin², Michael Golpanian², Julie Nusbaum³, Peter Izmirly⁴, Michael Belmont⁴, Shilpi Mehta-Lee² and Jill Buyon⁴, ¹New York University School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Long Island School of Medicine, Mineola, NY, ⁴NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with SLE may be at increased risk for developing a venous thromboembolism (VTE), particularly in the postpartum period. The Royal College of Obstetricians…
Abstract Number: 0988 • ACR Convergence 2022
Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Enpatoran Doses in a Phase I Study of Healthy Japanese and Caucasian Participants: Feasibility of Including Asian Participants in a Phase II Study of Enpatoran
Sathej Gopalakrishnan¹, Axel Krebs-Brown², Marco Nogueira Filho¹, Yoshihiro Kuroki³, Angelika Bachmann¹, Andreas Becker¹, Frank Schippers⁴, Markus Fluck¹, Özkan Yalkinoglu¹, Christine Kleinmond⁵, Denesh Chitkara⁶, Cristina Vazquez Mateo⁷, Sanjeev Roy⁸ and Lena Klopp-Schulze¹, ¹Translational Medicine, the healthcare business of Merck KGaA, Darmstadt, Germany, ²Global Biostatistics, the healthcare business of Merck KGaA, Darmstadt, Germany, ³Translational Medicine, Merck Biopharma Co., Ltd., an affiliate of Merck KGaA, Darmstadt, Germany, Tokyo, Japan, ⁴Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁵Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Global Clinical Development, EMD Serono, Billerica, MA, ⁷Global Clinical Development, EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ⁸Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany
Background/Purpose: Enpatoran, a novel, highly selective and potent dual toll-like receptor (TLR) 7 and TLR8 inhibitor, is in development for the treatment of autoimmune disorders…
Abstract Number: 1099 • ACR Convergence 2022
Empowering Patients with Lupus Through Their Photographs: Application of the Photovoice Method to Understand Social Determinants of Health
Sciaska Ulysse¹, Kreager Taber², Jessica Williams³, Laura Lorenz⁴ and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, MA, ²Duke University, Durham, NC, ³Emory University School of Medicine, Atlanta, GA, ⁴Brandeis University, Waltham, MA
Background/Purpose: Photovoice is a participatory visual research method that provides individuals with cameras and empowers them to share aspects of their daily lives and environments…
Abstract Number: 1273 • ACR Convergence 2022
Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: Data Availability and Preliminary Measure Performance in the RISE Registry
April Jorge¹, Alfredo Aguirre², April Barnado³, Bonnie Bermas⁴, Candace Feldman⁵, Shraddha Jatwani⁶, Alex Limanni⁷, JoAnn Zell⁸, Claire Barber⁹, Ali Duarte-Garcia¹⁰, Shivani Garg¹¹, Jing Li², Gabriela Schmajuk¹², Jinoos Yazdany¹³ and Christie Bartels¹⁴, ¹Massachusetts General Hospital, Boston, MA, ²University of California, San Francisco, San Francisco, CA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴UT Southwestern, Dallas, TX, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Albert Einstein Medical Center, Ambler, PA, ⁷Self, Dallas, TX, ⁸University of Colorado Anschutz Medical Campus, Denver, CO, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Mayo Clinic, Rochester, MN, ¹¹University of Madison, School of Medicine and Public Health, Madison, WI, ¹²UCSF / SFVA, San Francisco, CA, ¹³UCSF, San Francisco, CA, ¹⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Digital quality measures can facilitate monitoring and improvement of health care quality on a population level. As part of a CDC-funded ACR initiative to…
Abstract Number: 1374 • ACR Convergence 2022
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
Jordan Roberts¹, Mindy Lo¹, Rebecca Sadun², Emily Smitherman³, Scott Wenderfer⁴ and Mary Beth F. Son¹, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Duke University, Durham, NC, ³University of Alabama at Birmingham, Birmingham, AL, ⁴British Columbia Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Belimumab is the only targeted therapy approved for pediatric systemic lupus erythematosus (pSLE), although use remains limited in children. While clinical trials and studies…
Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Lifan Zhang¹, xiaoqing zou², Lantian Xie³, Jianghao Liu³, zhengrong yang⁴, qifei cao⁴, Chunlei Li⁵, Xiaochuan Sun⁵, Fengchun ZHANG⁶, Yan Zhao⁷, Xiaofeng Zeng⁸ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Beijing, China, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
Abstract Number: 1468 • ACR Convergence 2022
Apathy Measurement in a Cohort of Systemic Lupus Erythematosus
Mike Putman¹, David Gazeley² and Ikechukwu Mbonu³, ¹The Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Wauwatosa, WI, ³Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Up to 40% of patients with systemic lupus erythematosus (SLE) have measurable cognitive dysfunction on neuropsychiatric testing. Around 83% of patients are nonadherent with…
Abstract Number: 1538 • ACR Convergence 2022
Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes
Aya abugharbyeh, Sadik Khuder and bashar Kahaleh, University of Toledo, Toledo, OH
Background/Purpose: Evidence suggest that autoimmune diseases tend to coexist at a higher rate than expected, reflecting a common pathogenetic pathway. However, data sets have shown…
Abstract Number: 1692 • ACR Convergence 2022
Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
Shannon Estadt, Mehrnaz Gharaee-Kermani, Bin Xu, Tyson Moore, Andrew Hannoudi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by enhanced sensitivity to ultraviolet radiation (UVR). UVR can trigger cutaneous and systemic disease…
Abstract Number: 1726 • ACR Convergence 2022
Impaired Dynamic X-Chromosome Inactivation Maintenance in T Lymphocytes Is a Feature of Spontaneous Lupus in Female Mice and Is Exacerbated in Female-Biased Disease Models
Nikhil Jiwrajka¹, Natalie Toothacre², Zachary Beethem², Sarah Sting², Katherine Forsyth², Amanda Driscoll², William Stohl³ and Montserrat Anguera², ¹Division of Rheumatology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Department of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, ³University of Southern California, Los Angeles, CA
Background/Purpose: SLE is highly female-biased, yet the molecular origins of this bias remain unclear. The X chromosome contains many immune-related genes, suggesting that X-linked epigenetic…
Abstract Number: 2056 • ACR Convergence 2022
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Takehiro Nakai¹, Sho Fukui², Takahiro Asano³, Futoshi Iwata⁴, Hiroki Ozawa⁵, Satoshi Kawaai⁴, Yukihiko Ikeda¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁶, Kenichi YAMAGUCHI⁷ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Kyorin University Hospital, Tokyo, Japan, ³St. Luke's International Hospital, Chuo City Tokyo, Japan, ⁴St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].